Quick Answer
Larimar Therapeutics, Inc. reported Net Income of -$165.67 million for fiscal year 2025.
Larimar Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$165.67M | -105.5% |
| 2024 | -$80.60M | -118.1% |
| 2023 | -$36.95M | -4.5% |
| 2022 | -$35.35M | +30.2% |
| 2021 | -$50.64M | -19.2% |
| 2020 | -$42.48M | -83.7% |
| 2019 | -$23.13M | +62.3% |
| 2018 | -$61.37M | -18.0% |
| 2017 | -$52.03M | +10.1% |
| 2016 | -$57.88M | +22.1% |
| 2015 | -$74.29M | -103.6% |
| 2014 | -$36.48M | -160.1% |
| 2013 | -$14.03M | -1.1% |
| 2012 | -$13.88M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$47.71M | -207.8% | -82.2% |
| June 30, 2025 | -$26.18M | -21.1% | +10.6% |
| March 31, 2025 | -$29.28M | -99.8% | -88.9% |
| September 30, 2024 | -$15.50M | -71.0% | +28.3% |
| June 30, 2024 | -$21.63M | -158.5% | -47.6% |
| March 31, 2024 | -$14.65M | -124.5% | -61.7% |
| September 30, 2023 | -$9.06M | -8.9% | -8.3% |
| June 30, 2023 | -$8.37M | +3.5% | -28.2% |
- Larimar Therapeutics, Inc. showed a decrease of -105.5% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Larimar Therapeutics, Inc.’s net income has declined by 1093.6% (from -$13.88 million to -$165.67 million).
- The most recent figure is from Larimar Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: